Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.890
+0.010 (0.53%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Inhibikase Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Market Capitalization | 259 | 290 | 8 | 13 | 37 | 69 | |
| Market Cap Growth | -13.19% | 3596.14% | -37.83% | -65.89% | -46.68% | - | |
| Enterprise Value | 181 | 287 | -9 | -14 | -8 | 70 | |
| Last Close Price | 1.89 | 3.25 | 1.27 | 3.00 | 8.82 | 41.40 | |
| PS Ratio | - | - | 30.10 | 102.18 | 11.93 | 99.29 | |
| PB Ratio | 2.34 | 3.06 | 0.71 | 0.60 | 0.96 | 7.09 | |
| P/TBV Ratio | 3.55 | 3.06 | 0.71 | 0.60 | 0.96 | 7.09 | |
| EV/Sales Ratio | - | - | - | - | - | 100.29 | |
| Debt / Equity Ratio | - | 0.00 | 0.06 | 0.02 | 0.01 | 0.03 | |
| Net Debt / Equity Ratio | -1.06 | -1.03 | -1.15 | -1.08 | -1.05 | -1.39 | |
| Net Debt / EBITDA Ratio | 1.46 | 3.41 | 0.63 | 1.25 | - | - | |
| Net Debt / FCF Ratio | 3.02 | 5.09 | 0.70 | 1.29 | 2.83 | 12.07 | |
| Asset Turnover | - | - | 0.01 | 0.00 | 0.11 | 0.09 | |
| Quick Ratio | 11.55 | 26.13 | 3.85 | 6.25 | 10.08 | 2.96 | |
| Current Ratio | 11.73 | 26.37 | 4.13 | 6.60 | 10.48 | 3.13 | |
| Return on Equity (ROE) | -131.71% | -52.00% | -118.88% | -60.74% | -61.35% | -107.58% | |
| Return on Assets (ROA) | -79.11% | -31.60% | -63.67% | -33.62% | -32.24% | -23.77% | |
| Return on Capital Employed (ROCE) | -72.90% | -30.10% | -181.50% | -85.30% | -38.40% | -28.00% | |
| Earnings Yield | -18.43% | -9.50% | -242.67% | -143.13% | -39.99% | -4.11% | |
| FCF Yield | -9.91% | -6.61% | -230.82% | -139.49% | -38.66% | -1.63% | |
| Buyback Yield / Dilution | -1147.76% | -1379.34% | -42.74% | -39.15% | -121.72% | -0.39% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.